skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

De-stiffening drug therapy and blood pressure control

Review

(2581) Views  (918) Full article downloads

Authors: Michel E Safar

Published Date January 2010 Volume 2010:3 Pages 1 - 9
DOI: http://dx.doi.org/10.2147/IBPC.S6635

Michel E Safar

Paris-Descartes University, Faculty of Medicine, Hôtel-Dieu Hospital, AP-HP, Diagnosis Center, Paris, France

Abstract: In hypertensive subjects, cardiovascular risk reduction is critically related to the decrease of systolic blood pressure (SBP). De-stiffening therapy means that, in a controlled therapeutic trial of long duration, a selective reduction of SBP has been obtained in the studied group by comparison with the control group, and that this SBP reduction is due to a decrease of either arterial stiffness, or wave reflections, or both. Central SBP reduction and cardiovascular remodeling are specifically involved. Most protocols require the presence of an angiotensin II blocker, potentially associated with a diuretic compound and/or a calcium-channel blocker. Cardiovascular outcomes are significantly reduced by comparison with the control group, particularly when this latter group involves administration of a betablocking agent.

Keywords: hypertension, pulse pressure, large arteries, de-stiffening drug therapy






 

Other articles by Professor Michel Safar



Readers of this article also read:

Antihypertensive effects of astaxanthin
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials
Clinical approach in treatment of resistant hypertension
Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness
Long-term use and tolerability of irbesartan for control of hypertension
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University